Our Mission
Pancreatic cancer is the third leading cause of cancer death globally. The 5-year survival rate hovers around 12%. For the 20% of patients who qualify for curative surgery, the single biggest determinant of outcome is surgical volume — how many procedures the surgeon and hospital perform each year.
Shanghai has the highest concentration of high-volume hepatobiliary-pancreatic surgical centers in Asia. The data is publicly available, published in international journals. This isn't a claim — it's a fact.
Surgical Volume: The Numbers That Matter
The volume-outcome relationship in pancreatic surgery is one of the strongest in all of medicine. Higher volume = lower mortality, better R0 resection rates, fewer complications. Shanghai doesn't just meet the threshold — it exceeds it dramatically.
For context: a typical high-volume US cancer center performs 100–200 pancreatic resections per year. Shanghai's top centers do 3–6x that volume. More repetitions mean sharper skills, faster decision-making during surgery, and better management of complications. This is basic surgical science — and it's the reason patients should care about volume.
Clinical Trials & Innovation: Access to Tomorrow's Medicine
China is now the world's second-largest clinical trial market. Shanghai's hospitals are at the center of this — running hundreds of active oncology trials, many of which are unavailable or prohibitively expensive in the West.
For patients who have exhausted standard treatment options, or who cannot afford the cost of cutting-edge therapies in the US or UK, Shanghai offers access to a new generation of cancer drugs through clinical trials — often at no cost to the patient.
KRAS Inhibitors
Multiple KRAS G12C and pan-KRAS inhibitor trials recruiting at Shanghai hospitals. For patients with KRAS-mutant pancreatic cancer — a mutation found in ~90% of cases.
mRNA Cancer Vaccines
Personalized neoantigen vaccines (mRNA-based) for pancreatic cancer. Several China-developed candidates are in Phase II trials at Shanghai centers.
Bispecific Antibodies
T-cell engaging bispecific antibodies targeting tumor-associated antigens. Shanghai is a leading trial site for several China-developed bispecifics.
ADC & CAR-T Therapies
Antibody-drug conjugates and CAR-T cell therapies for solid tumors. China has the largest number of CAR-T trials globally — many at Shanghai hospitals.
Why this matters for Western patients:
In the US, a course of a novel targeted therapy can cost $150,000–$300,000 out of pocket. In a clinical trial, the drug is provided free. For patients who cannot afford these prices (and most can't), a clinical trial in Shanghai may be the only realistic path to accessing tomorrow's medicine today. This isn't charity — it's the structure of global clinical research.
Recovery & Rehabilitation
Shanghai's advantages don't end in the operating room. China has invested heavily in post-acute care and rehabilitation infrastructure — and Shanghai leads the country.
- Dedicated Post-Surgical Wards
International wards with private rooms, adjustable beds, patient-controlled analgesia (PCA), and 24/7 nursing ratios that match or exceed Western standards.
- Nutritional Rehabilitation
Dietitian-supervised recovery diets. Gradual progression from liquid to solid food, optimized for pancreatic surgery patients. Enteral nutrition support when needed.
- Physical Rehabilitation
Early mobilization programs starting Day 1 post-op. Physiotherapy for abdominal surgery recovery. Guided walking protocols that reduce complication rates.
- Traditional Chinese Medicine Integration (Optional)
Many hospitals offer optional TCM support during recovery — acupuncture for pain management, herbal formulas for appetite restoration. Always discussed with your surgical team first.
- Remote Follow-Up Infrastructure
Video consultation capability for post-discharge follow-up. Your Shanghai surgeon remains accessible after you fly home. Digital pathology sharing with your home oncologist.
Shanghai also offers excellent general living conditions for recovering patients and their companions: international-standard hotels near major hospitals, English-speaking services, food options for every dietary requirement, and one of the safest major cities in the world.
The Honest Case for Shanghai
We're not asking you to take a leap of faith. We're asking you to look at the data.
Surgical volume: Shanghai's top centers do more pancreatic resections per year than any single hospital in the US, UK, or Australia. More volume means better outcomes. This is published, peer-reviewed, and uncontested.
Outcomes: Published mortality rates of 1.5–3%, R0 resection rates of 70–80%. This is comparable to — and in some cases better than — Memorial Sloan Kettering, Johns Hopkins, and the Royal Marsden.
Cost: $11,000–$28,000 for a Whipple procedure. That's 70–85% less than the US, 60–75% less than UK private. Not because the quality is lower — because the system is different.
Innovation: Access to clinical trials for KRAS inhibitors, mRNA vaccines, bispecific antibodies, and CAR-T therapies — often at no cost to the patient.
Access: 30-day visa-free entry for 47+ countries. Surgery scheduled within 2–4 weeks. No 6-month NHS waits. No $200,000 insurance battles.
Recovery: World-class post-surgical wards, rehabilitation programs, nutritional support, and remote follow-up infrastructure.
The bottom line:
If you have resectable pancreatic cancer and you're facing a long wait or an impossible price at home — Shanghai is not a compromise. It's a calculated, evidence-based decision that gives you access to experienced surgeons, cutting-edge treatments, and professional recovery care at a cost that doesn't bankrupt your family. The only question is whether you can afford to wait while you think about it.
Who We Are
MedInSh is an independent medical information platform. We are not affiliated with any hospital, insurance company, or pharmaceutical company. We do not receive referral fees or commissions.
Our content is based on published medical literature, publicly available hospital data, and first-hand accounts from patients who have undergone treatment in Shanghai. We update our guides regularly as new data becomes available.
This website does not provide medical advice. All treatment decisions should be made in consultation with your treating physician.
Ready to Learn More?
Start with our patient guides, or explore the practical steps of medical travel to Shanghai.